Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.710
-0.040 (-5.33%)
At close: Apr 28, 2026

Lyra Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2018
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2018
Market Capitalization
151427510057
Upgrade
Market Cap Growth
-81.42%-59.54%-95.09%175.61%76.26%-61.52%
Upgrade
Enterprise Value
1615-3179-90
Upgrade
Last Close Price
0.703.0810.32262.00157.00218.00
Upgrade
PS Ratio
3.1413.748.81176.7973.32198.95
Upgrade
PB Ratio
-0.12-0.511.173.081.241.65
Upgrade
P/TBV Ratio
--1.173.081.241.65
Upgrade
EV/Sales Ratio
39.2437.16-115.00-0.97
Upgrade
Debt / Equity Ratio
-2.82-2.822.970.300.030.04
Upgrade
Net Debt / Equity Ratio
-1.34-1.34-0.53-0.85-1.18-1.29
Upgrade
Net Debt / EBITDA Ratio
-0.49-0.490.101.161.771.04
Upgrade
Net Debt / FCF Ratio
-0.50-0.500.091.182.201.52
Upgrade
Asset Turnover
0.010.010.020.010.020.00
Upgrade
Quick Ratio
1.671.673.215.246.772.51
Upgrade
Current Ratio
1.711.713.415.356.972.63
Upgrade
Return on Equity (ROE)
-6594.98%-6594.98%-184.99%-73.67%-96.08%-79.98%
Upgrade
Return on Assets (ROA)
-36.06%-36.06%-36.33%-32.43%-41.70%-40.18%
Upgrade
Return on Capital Employed (ROCE)
-111.20%-111.20%-113.10%-53.30%-57.60%-119.10%
Upgrade
Earnings Yield
-2311.13%-529.01%-691.58%-22.76%-55.31%-76.74%
Upgrade
FCF Yield
-2315.61%-530.03%-535.50%-23.36%-43.58%-51.51%
Upgrade
Buyback Yield / Dilution
-19.29%-19.29%-30.74%-64.72%-132.83%-51.17%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.